Sanofi SNY has entered into exclusive negotiations with U.S.-based private equity company Clayton Dubilier & Rice (CD&R) for ...

Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Sarclisa in combination with the VRd regiment was superior to VRd alone in improving survival in stem cell transplant ...

When Sanofi announced last week that it plans to sell a 50% controlling stake of Opella, its consumer helath business, the ...

Products will be made at six of Sanofi’s European API production sites ... Management is trying to decide further details such as whether to list the separated business on the Euronext Paris ...

Six years ago, Sanofi gave $125 million and promised over $1 billion in milestone payments to buzzy neuroscience startup ...

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

PARIS, Oct 11 (Reuters) - Sanofi (SASY.PA), opens new tab has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier ...

Sanofi is now in “exclusive negotiations ... Some of its most popular products include the antihistamine Allegra, non-opioid pain reliever Doliprane, stomach cramp reliever Buscopan, Selsun ...

Furthermore, the potential side effects of rocatinlimab suggest a tolerability advantage for Sanofi’s products. Parry’s analysis suggests that rocatinlimab will likely be used post-Dupixent ...

US planemaker Boeing is heading into a busy week, with investors watching developments closely around its costly labour strike, as well as its latest quarterly results. More than 33,000 unionised ...